Belpointe Asset Management LLC Sells 374 Shares of Repligen Co. (NASDAQ:RGEN)

Belpointe Asset Management LLC trimmed its holdings in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 42.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 508 shares of the biotechnology company’s stock after selling 374 shares during the quarter. Belpointe Asset Management LLC’s holdings in Repligen were worth $86,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in RGEN. Vanguard Group Inc. boosted its stake in shares of Repligen by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,128,884 shares of the biotechnology company’s stock worth $959,665,000 after acquiring an additional 24,998 shares during the last quarter. Invesco Ltd. raised its stake in Repligen by 3.9% during the 1st quarter. Invesco Ltd. now owns 1,756,157 shares of the biotechnology company’s stock worth $330,315,000 after acquiring an additional 65,550 shares during the period. Sands Capital Management LLC purchased a new position in Repligen during the third quarter valued at approximately $306,666,000. WCM Investment Management LLC lifted its holdings in Repligen by 5.4% during the fourth quarter. WCM Investment Management LLC now owns 1,601,982 shares of the biotechnology company’s stock valued at $271,232,000 after purchasing an additional 82,356 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Repligen by 1.3% in the third quarter. State Street Corp now owns 1,393,580 shares of the biotechnology company’s stock worth $260,753,000 after purchasing an additional 18,369 shares during the period. 91.00% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Repligen news, Director Martin D. Madaus acquired 500 shares of Repligen stock in a transaction dated Monday, May 8th. The stock was acquired at an average cost of $156.18 per share, for a total transaction of $78,090.00. Following the completion of the transaction, the director now owns 1,611 shares in the company, valued at approximately $251,605.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. StockNews.com initiated coverage on shares of Repligen in a report on Thursday. They issued a “sell” rating for the company. KeyCorp decreased their target price on Repligen from $260.00 to $240.00 and set an “overweight” rating on the stock in a research note on Thursday, February 23rd. Royal Bank of Canada dropped their price target on Repligen from $170.00 to $157.00 in a research note on Wednesday, May 3rd. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Repligen from $180.00 to $165.00 in a research report on Wednesday, May 3rd. Finally, Benchmark cut their target price on shares of Repligen from $230.00 to $210.00 in a research note on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $208.56.

Repligen Trading Up 1.7 %

RGEN stock opened at $159.25 on Friday. The company has a market cap of $8.87 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 2.76 and a beta of 1.08. The firm has a 50 day moving average of $163.39 and a 200-day moving average of $173.10. Repligen Co. has a 12-month low of $137.65 and a 12-month high of $262.26.

Repligen (NASDAQ:RGEN – Get Rating) last released its quarterly earnings data on Tuesday, May 2nd. The biotechnology company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.05. The business had revenue of $182.70 million for the quarter, compared to analyst estimates of $181.43 million. Repligen had a return on equity of 9.14% and a net margin of 21.58%. The company’s revenue was down 11.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.92 EPS. Sell-side analysts forecast that Repligen Co. will post 2.37 earnings per share for the current fiscal year.

Repligen Company Profile

(Get Rating)

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G.